{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:17:34Z","timestamp":1792804654576,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boehringer"},{"name":"Innovaderm"},{"DOI":"10.13039\/100009689","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009689","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Paraxel"},{"name":"Kineta"},{"name":"Leo Pharma"},{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vitae"},{"name":"Innovaderm"},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novan"},{"name":"Janssen"},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sienna"},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jaci.2019.04.029","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T21:37:24Z","timestamp":1558647444000},"page":"750-763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":184,"title":["IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis"],"prefix":"10.1016","volume":"144","author":[{"given":"James G.","family":"Krueger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Keith A.","family":"Wharton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schlitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Suprun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca I.","family":"Torene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire Q.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judilyn","family":"Fuentes-Duculan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Koroleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Hillenbrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Letzkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Glueck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Hasselberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Flannery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayte","family":"Su\u00e1rez-Fari\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hueber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2019.04.029_bib1","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a015354","article-title":"Psoriasis","volume":"4","author":"Di Meglio","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jaci.2019.04.029_bib2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaad.2008.01.006","article-title":"National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening","volume":"58","author":"Kimball","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.04.029_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.det.2014.09.004","article-title":"Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities","volume":"33","author":"Ryan","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaci.2019.04.029_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1573397111309010002","article-title":"Psoriasis vulgaris and psoriasis pustulosa\u2014epidemiology, quality of life, comorbidities and treatment","volume":"9","author":"Pfohler","year":"2013","journal-title":"Curr Rheumatol Rev"},{"key":"10.1016\/j.jaci.2019.04.029_bib5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaci.2019.04.029_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.det.2014.09.002","article-title":"The immunopathogenesis of psoriasis","volume":"33","author":"Kim","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaci.2019.04.029_bib7","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.04.029_bib8","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1590\/abd1806-4841.20143210","article-title":"Expression of lymphatic markers and lymphatic growth factors in psoriasis before and after anti-TNF treatment","volume":"89","author":"Moustou","year":"2014","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.jaci.2019.04.029_bib9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s004030050340","article-title":"Immunohistochemical study of epidermal nerve fibres in involved and uninvolved psoriatic skin using confocal laser scanning microscopy","volume":"290","author":"Pergolizzi","year":"1998","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaci.2019.04.029_bib10","doi-asserted-by":"crossref","first-page":"19295","DOI":"10.1038\/srep19295","article-title":"Transcriptome profiling unveils the role of cholesterol in IL-17A signaling in psoriasis","volume":"6","author":"Varshney","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2019.04.029_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jaad.2013.12.036","article-title":"Interleukin 17A: toward a new understanding of psoriasis pathogenesis","volume":"71","author":"Lynde","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.04.029_bib12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1359-6101(03)00002-9","article-title":"Interleukin-17 family and IL-17 receptors","volume":"14","author":"Moseley","year":"2003","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jaci.2019.04.029_bib13","doi-asserted-by":"crossref","first-page":"e90284","DOI":"10.1371\/journal.pone.0090284","article-title":"IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model","volume":"9","author":"Chiricozzi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2019.04.029_bib14","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1038\/ncomms6621","article-title":"The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis","volume":"5","author":"Lande","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2019.04.029_bib15","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2019.04.029_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aat4617","article-title":"IL-17 integrates multiple self-reinforcing, feed-forward mechanisms through the RNA binding protein Arid5a","volume":"11","author":"Amatya","year":"2018","journal-title":"Sci Signal"},{"key":"10.1016\/j.jaci.2019.04.029_bib17","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2019.04.029_bib18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.immuni.2011.09.010","article-title":"Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E","volume":"35","author":"Chang","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2019.04.029_bib19","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.97179","article-title":"Chronic skin inflammation accelerates macrophage cholesterol crystal formation and atherosclerosis","volume":"3","author":"Baumer","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2019.04.029_bib20","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/s12967-015-0738-z","article-title":"Chronic, not acute, skin-specific inflammation promotes thrombosis in psoriasis murine models","volume":"13","author":"Golden","year":"2015","journal-title":"J Transl Med"},{"key":"10.1016\/j.jaci.2019.04.029_bib21","first-page":"1092","article-title":"Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways","volume":"159","author":"Nograles","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2019.04.029_bib22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2019.04.029_bib23","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028522","article-title":"Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications","volume":"10","author":"Monin","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.jaci.2019.04.029_bib24","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2019.04.029_bib25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2019.04.029_bib26","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2019.04.029_bib27","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Thaci","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.04.029_bib28","doi-asserted-by":"crossref","first-page":"e44274","DOI":"10.1371\/journal.pone.0044274","article-title":"Meta-analysis derived (MAD) transcriptome of psoriasis defines the \u201ccore\u201d pathogenesis of disease","volume":"7","author":"Tian","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2019.04.029_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"Hanzelmann","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jaci.2019.04.029_bib30","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study","volume":"137","author":"Krueger","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.04.029_bib31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis","volume":"130","author":"Krueger","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.04.029_bib32","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/jid.2008.4","article-title":"Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness","volume":"128","author":"Guttman-Yassky","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2019.04.029_bib33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1755-8794-7-27","article-title":"Cellular dissection of psoriasis for transcriptome analyses and the post-GWAS era","volume":"7","author":"Swindell","year":"2014","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.jaci.2019.04.029_bib34","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1152\/physiolgenomics.00022.2014","article-title":"Integrative RNA-seq and microarray data analysis reveals GC content and gene length biases in the psoriasis transcriptome","volume":"46","author":"Swindell","year":"2014","journal-title":"Physiol Genomics"},{"key":"10.1016\/j.jaci.2019.04.029_bib35","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1084\/jem.20071094","article-title":"Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses","volume":"204","author":"Zaba","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2019.04.029_bib36","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.4049\/jimmunol.180.3.1913","article-title":"Identification of cellular pathways of \u201ctype 1,\u201d Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A\u00a0in psoriasis","volume":"180","author":"Haider","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2019.04.029_bib37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2353\/ajpath.2007.061067","article-title":"The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: dominance of innate immune responses in psoriasis","volume":"171","author":"Mee","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaci.2019.04.029_bib38","doi-asserted-by":"crossref","first-page":"e2737","DOI":"10.1371\/journal.pone.0002737","article-title":"Type I interferon: potential therapeutic target for psoriasis?","volume":"3","author":"Yao","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2019.04.029_bib39","doi-asserted-by":"crossref","first-page":"e34594","DOI":"10.1371\/journal.pone.0034594","article-title":"Heterogeneity of inflammatory and cytokine networks in chronic plaque psoriasis","volume":"7","author":"Swindell","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2019.04.029_bib40","doi-asserted-by":"crossref","first-page":"R54","DOI":"10.1186\/gb-2006-7-7-r54","article-title":"Signatures of human regulatory T cells: an encounter with old friends and new players","volume":"7","author":"Pfoertner","year":"2006","journal-title":"Genome Biol"},{"key":"10.1016\/j.jaci.2019.04.029_bib41","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1038\/jid.2014.268","article-title":"IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood","volume":"134","author":"Wang","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2019.04.029_bib42","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1038\/jid.2010.165","article-title":"A subpopulation of CD163-positive macrophages is classically activated in psoriasis","volume":"130","author":"Fuentes-Duculan","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2019.04.029_bib43","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jaci.2009.08.046","article-title":"Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes","volume":"124","author":"Zaba","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.04.029_bib44","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1038\/jid.2010.36","article-title":"Assessment of the psoriatic transcriptome in a large sample: additional regulated\u00a0genes and comparisons with in\u00a0vitro models","volume":"130","author":"Gudjonsson","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2019.04.029_bib45","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/jid.2009.173","article-title":"Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin","volume":"129","author":"Gudjonsson","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2019.04.029_bib46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jaad.2018.03.046","article-title":"Commentary: does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality?: a critical question that we are only just beginning to answer","volume":"79","author":"Gelfand","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.04.029_bib47","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1001\/jama.1986.03380220076026","article-title":"Cyclosporine improves psoriasis in a double-blind study","volume":"256","author":"Ellis","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2019.04.029_bib48","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/exd.12710","article-title":"Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis","volume":"24","author":"Reich","year":"2015","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2019.04.029_bib49","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.04.029_bib50","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2019.04.029_bib51","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.4049\/jimmunol.1301737","article-title":"Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody","volume":"192","author":"Russell","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2019.04.029_bib52","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/cei.12761","article-title":"Distinct expression of interleukin (IL)-36alpha, beta and gamma, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease","volume":"184","author":"Boutet","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2019.04.029_bib53","doi-asserted-by":"crossref","first-page":"10088","DOI":"10.1073\/pnas.1801377115","article-title":"IkappaBzeta is a key transcriptional regulator of IL-36-driven psoriasis-related gene expression in keratinocytes","volume":"115","author":"Muller","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2019.04.029_bib54","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMc1811317","article-title":"Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis","volume":"380","author":"Bachelez","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2019.04.029_bib55","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.4049\/jimmunol.178.4.2229","article-title":"The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis","volume":"178","author":"Sa","year":"2007","journal-title":"J Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674919306827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674919306827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:19:04Z","timestamp":1758791944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674919306827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0091674919306827"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2019.04.029","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2019.04.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}